These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 28894080)

  • 1. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update.
    Araújo FC; Sepriano A; Teixeira F; Jesus D; Rocha TM; Martins P; Tenazinha C; Cordeiro A; Mourão AF; Silva C; Vaz C; Duarte C; Ponte C; Dos Santos FP; Canhão H; Santos H; Pimentão JB; da Silva JC; Pereira J; da Silva JAP; Miranda LC; Oliveira M; Saavedra MJ; Gonçalves P; Falcão S; Capela S; Fonseca JE
    Acta Reumatol Port; 2017; 42(3):219-228. PubMed ID: 28894080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Fonseca JE; Gonçalves J; Araújo F; Cordeiro I; Teixeira F; Canhão H; da Silva JA; Garcês S; Miranda LC; Ramiro S; Roxo A; Pimentel-Santos FM; Tavares V; Neto A; Sepriano A; Malcata A; Faustino A; Silva C; Ambrósio C; Duarte C; Miguel C; Barcelos F; Santos H; Cunha I; Ramos JC; Gomes JA; Pimentão JB; Costa L; Maurício L; Silva M; Bernardes M; Bogas M; Coelho PC; Monteiro P; Aguiar R; André R; Leitão R; Pimenta S; Meirinhos T; Fernandes S; Las V; Castelão W;
    Acta Reumatol Port; 2014; 39(1):60-71. PubMed ID: 24811463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PANLAR consensus statement on biosimilars.
    Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
    Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars in rheumatology: current perspectives and lessons learnt.
    Dörner T; Kay J
    Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars in rheumatology.
    Araújo FC; Gonçalves J; Fonseca JE
    Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing landscape of biosimilars in rheumatology.
    Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
    Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on: The Portuguese Society of Rheumatology position paper on the use of biosimilars.
    Müller-Ladner U
    Acta Reumatol Port; 2014; 39(1):7-8. PubMed ID: 24811455
    [No Abstract]   [Full Text] [Related]  

  • 8. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
    Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
    Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Position Paper from the Portuguese Association of Hospital Pharmacists for biosimilar therapeutic antibodies.
    Goncalves J; Matos de Brito P; Batista A; Feio J; Machado F; Aperta J; Ascensão I; Pires V; Oliveira C; Armandina Pontes R; Alcobia A; Paulo Cruz J; Lampreia Guerreiro S; Farinha H; Margarida Freitas A; Caetano M; Almeida P; Costa B; Oliveira C; Campos C; Madureira B; Cavaco M; Catarino H;
    J Clin Pharm Ther; 2017 Apr; 42(2):239-243. PubMed ID: 27859438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
    Schaeverbeke T; Pham T; Richez C; Wendling D
    Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of Biosimilars: A Systematic Review of Published Position Statements and Recommendations from Health Organisations and Societies.
    Mohd Sani N; Aziz Z; Kamarulzaman A
    BioDrugs; 2024 May; 38(3):405-423. PubMed ID: 38472644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Position paper from the Spanish Society of Rheumatology on biosimilar drugs.
    Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV
    Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
    Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The road from development to approval: evaluating the body of evidence to confirm biosimilarity.
    Declerck P; Farouk Rezk M
    Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Regulation of Biosimilars in Latin America.
    Garcia R; Araujo DV
    Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Position paper of Italian rheumatologists on the use of biosimilar drugs.
    Atzeni F; Sebastiani M; Ricci C; Celano A; Gremese E; Iannone F; Meroni PL; Minghetti P; Sarzi-Puttini P; Ferraccioli G; Lapadula G
    Clin Exp Rheumatol; 2015; 33(1):1-4. PubMed ID: 25436597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Experience with Biosimilars of Infliximab in Rheumatic Diseases.
    Azevedo VF; Kos IA; Ariello L
    Curr Pharm Des; 2017; 23(44):6752-6758. PubMed ID: 29189135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on biosimilars in rheumatology.
    Rischin A; Östör AJ
    Inflammopharmacology; 2017 Apr; 25(2):177-184. PubMed ID: 28265837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars in pediatric rheumatology and their introduction into routine care.
    Aragon Cuevas O; Hedrich CM
    Clin Immunol; 2020 Jul; 216():108447. PubMed ID: 32360950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.